Goerg A, Piendl G, Albert V, Ortmann O, et al. Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition. BMC Cancer 2025;25:978.
PMID: 40452017